No Data
Jimin Health (603222.SH): plans to spend 0.1 billion to 0.2 billion yuan to repurchase shares.
On March 28, Gu Long Hui announced that Jimin Health (603222.SH) plans to use the repurchased shares for employee stock ownership plans or Stock-based Incentive, with the repurchase amount not less than 0.1 billion yuan (inclusive) and not exceeding 0.2 billion yuan (inclusive); the repurchase price not exceeding 10.00 yuan/share (inclusive).
Chimin Health Management (SHSE:603222 Shareholders Incur Further Losses as Stock Declines 11% This Week, Taking Five-year Losses to 84%
Chimin Health Management Vice President Accused of Fraudulent Activities; Shares Slump 10%
The vice president privately carved a "radish seal"! Jimin Health urgently reported to the police, and the stock price plummeted to the limit.
In recent years, performance has come under pressure.
Accused of forging a seal, achieving a sales volume of 0.117 billion in two years. Jimin Health is suing its own vice president. Can Dealers get their payment back? | Quick read announcement.
① The stamp of Jimin Health is identified as "forged," and the investigation revealed the existence of a "supplementary agreement"; ② Jimin Health is at risk of being sued by Dealers, stating that "it will actively communicate with the involved Dealers to seek a proper solution"; ③ The industry believes that the involved vice president may have undertaken a considerable sales task, thus "taking a risk," while it's very difficult for suppliers to recover the payments in the short term.
Jimin Health (603222.SH): The vice president is suspected of committing a crime, and the company has reported the case and received a notice of filing.
On March 26, 2023, Gelonghui reported that Jimin Health (603222.SH) announced that the company recently received letters from some Dealers, stating that in addition to signing the "Dealer Agreement" with the company, they also signed a "Supplementary Agreement." They required the company to perform its return and refund obligations as stipulated in the "Supplementary Agreement" and to pay compensation for the occupation of funds. After receiving the above letters, the company immediately initiated an investigation into the related matters. The investigation found that the company's Vice President He Qinghong and his team members forged the company's and its subsidiaries' (Jumin Biotechnology Co., Ltd., Zhejiang Jimin Tang Pharmaceutical Trading Co., Ltd.)
Chimin Health Management Co., Ltd.'s (SHSE:603222) 28% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio
